Regeneron Pharmaceuticals (REGN) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $543.7 million.
- Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization rose 1259.06% to $543.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $543.7 million, marking a year-over-year increase of 1259.06%. This contributed to the annual value of $543.7 million for FY2025, which is 1259.06% up from last year.
- Per Regeneron Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $543.7 million for Q4 2025, which was up 1259.06% from $482.9 million recorded in Q4 2024.
- Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $543.7 million during Q4 2025, with a 5-year trough of $286.2 million in Q4 2021.
- Its 5-year average for Accumulated Depreciation & Amortization is $415.0 million, with a median of $421.0 million in 2023.
- In the last 5 years, Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization skyrocketed by 2331.58% in 2023 and then surged by 1259.06% in 2025.
- Over the past 5 years, Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $286.2 million in 2021, then rose by 19.29% to $341.4 million in 2022, then rose by 23.32% to $421.0 million in 2023, then grew by 14.7% to $482.9 million in 2024, then grew by 12.59% to $543.7 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $543.7 million for Q4 2025, versus $482.9 million for Q4 2024 and $421.0 million for Q4 2023.